Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Research & Development (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Research & Development for 6 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 33.7% to $57.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $195.7 million through Dec 2025, up 38.5% year-over-year, with the annual reading at $195.7 million for FY2025, 38.5% up from the prior year.
  • Research & Development for Q4 2025 was $57.6 million at 4D Molecular Therapeutics, up from $49.4 million in the prior quarter.
  • The five-year high for Research & Development was $57.6 million in Q4 2025, with the low at $12.8 million in Q1 2021.
  • Average Research & Development over 5 years is $28.8 million, with a median of $24.3 million recorded in 2023.
  • The sharpest move saw Research & Development fell 3.16% in 2021, then surged 65.54% in 2024.
  • Over 5 years, Research & Development stood at $17.5 million in 2021, then rose by 22.66% to $21.5 million in 2022, then grew by 21.06% to $26.0 million in 2023, then soared by 65.54% to $43.1 million in 2024, then soared by 33.7% to $57.6 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $57.6 million, $49.4 million, and $48.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.